Status:
UNKNOWN
A Real-world Study of Albumin-bound Paclitaxel in the Treatment of Pancreatic Cancer
Lead Sponsor:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18-80 years
Brief Summary
Pancreatic cancer progresses rapidly and has a higher death rate. Albumin-bound paclitaxel is a new generation of paclitaxel . Albumin-bound paclitaxel is recommended as a class 1A evidence treating p...
Detailed Description
This is a prospective, single-arm, observational study. After the subjects meet the inclusive and exclusive criteria, then they will receive albumin-bound paclitaxel treatment. The researchers can cho...
Eligibility Criteria
Inclusion
- Age: 18 -80, male or female;
- Non-operative patients with locally advanced or metastatic pancreatic cancer diagnosed by pathology or histology (except islet cell carcinoma);
- The patient has not received standard systematic treatment in the past, and the metastatic site has not received any local treatment, including radiotherapy, chemotherapy, surgical treatment, etc.;
- At least one measurable lesion (CT scan length of tumor lesion is greater than 10 mm, CT scan short diameter of lymph node lesion is greater than 15 mm, scanning layer thickness is not greater than 5 mm);
- The subjects volunteered to participate in this study and signed the informed consent form, with good compliance to follow-up.
Exclusion
- Pregnant or lactating women;
- Patients allergy to albumin-bound paclitaxel or its excipients
- Patients with albumin-bound paclitaxel contraindication;
- Doctors consider those who are not suitable for this study.
Key Trial Info
Start Date :
December 20 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2020
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT03768687
Start Date
December 20 2018
End Date
June 1 2020
Last Update
December 10 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China, 210008